Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Amazon
AMZN
|
$529M |
| 2 |
Apple
AAPL
|
$498M |
| 3 |
Procter & Gamble
PG
|
$497M |
| 4 |
Elanco Animal Health
ELAN
|
$467M |
| 5 |
AbbVie
ABBV
|
$397M |
Top Sells
| 1 |
Microsoft
MSFT
|
$696M |
| 2 |
Intuit
INTU
|
$535M |
| 3 |
Alphabet (Google) Class C
GOOG
|
$503M |
| 4 |
Intercontinental Exchange
ICE
|
$459M |
| 5 |
Boeing
BA
|
$420M |
Sector Composition
| 1 | Technology | 28.58% |
| 2 | Healthcare | 18.93% |
| 3 | Financials | 10.61% |
| 4 | Consumer Discretionary | 10.26% |
| 5 | Industrials | 8.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
DexCom
DXCM
$31.7B
| $211M | 0.15% |
3,139,968
+796,424
| +34% | +$53.6M |
|
152
HP
HPQ
$27B
| $211M | 0.15% |
12,163,175
+1,149,798
| +10% | +$20M |
|
153
RB Global
RBA
$21.5B
| $211M | 0.15% |
6,176,838
-2,905
| -0% | -$99.3K |
|
154
Frontdoor
FTDR
$4.61B
| $210M | 0.14% |
6,049,154
-555,336
| -8% | -$19.3M |
|
155
Ascendis Pharma
ASND
$12B
| $210M | 0.14% |
1,867,190
+614,186
| +49% | +$69.2M |
|
|
RP
156
DELISTED
RealPage, Inc.
RP
| $208M | 0.14% |
3,931,826
-532,800
| -12% | -$28.2M |
|
157
Southern Company
SO
$101B
| $201M | 0.14% |
3,717,616
+74,848
| +2% | +$4.05M |
|
|
VAR
158
DELISTED
Varian Medical Systems, Inc.
VAR
| $200M | 0.14% |
1,952,913
-223,159
| -10% | -$22.9M |
|
159
Sealed Air
SEE
$4.75B
| $200M | 0.14% |
8,110,605
-99,478
| -1% | -$2.46M |
|
160
NRG Energy
NRG
$28.6B
| $200M | 0.14% |
7,344,429
+2,424,235
| +49% | +$66.1M |
|
161
Flex
FLEX
$20.6B
| $200M | 0.14% |
31,611,734
+1,277,810
| +4% | +$8.06M |
|
|
HZNP
162
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $198M | 0.14% |
6,682,922
+807,303
| +14% | +$23.9M |
|
163
Starbucks
SBUX
$98.9B
| $198M | 0.14% |
3,010,995
+1,705,058
| +131% | +$112M |
|
164
Ingersoll Rand
IR
$31.5B
| $197M | 0.14% |
7,950,062
+5,563,706
| +233% | +$138M |
|
165
Pfizer
PFE
$140B
| $194M | 0.13% |
6,275,749
-2,056,744
| -25% | -$63.7M |
|
166
Bank of America
BAC
$375B
| $193M | 0.13% |
9,099,052
-2,666,814
| -23% | -$56.6M |
|
167
Aramark
ARMK
$10.3B
| $192M | 0.13% |
13,343,464
+1,164,892
| +10% | +$16.8M |
|
168
Integra LifeSciences
IART
$1.22B
| $192M | 0.13% |
4,305,926
-6,921
| -0.2% | -$309K |
|
169
Monster Beverage
MNST
$62B
| $192M | 0.13% |
6,834,576
+2,501,384
| +58% | +$70.4M |
|
170
Newmont
NEM
$82.3B
| $192M | 0.13% |
4,246,472
+590,418
| +16% | +$26.7M |
|
171
Aptiv
APTV
$17.5B
| $192M | 0.13% |
3,897,108
-51,070
| -1% | -$2.51M |
|
172
Clarivate
CLVT
$2.86B
| $189M | 0.13% |
9,100,361
-368,585
| -4% | -$7.65M |
|
173
Cimpress
CMPR
$1.49B
| $187M | 0.13% |
3,513,089
-96,944
| -3% | -$5.16M |
|
174
Analog Devices
ADI
$121B
| $186M | 0.13% |
2,075,383
+636,753
| +44% | +$57.1M |
|
175
Berkshire Hathaway Class B
BRK.B
$1.09T
| $184M | 0.13% |
1,008,231
-23,290
| -2% | -$4.26M |
|